The first quarter of 2021 witnessed continued resiliency in biopharma financing and deal-making, with pharma and investor appetites showing no signs of slowing after an active 2020. The volume of follow-on offerings and IPOs was up sharply for the quarter year-on-year, as was venture capital financing volume, with valuations remaining strong.
Download our report to learn more about the 500+ deals that took place in Q1 2021 and see which therapy areas and companies drove the largest share of financing and deal-making.